HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures.

Abstract
Brivaracetam is a selective, high-affinity ligand for synaptic vesicle protein 2A, recently approved as adjunctive therapy in the treatment of focal (partial-onset) seizures in patients 16 years of age and older with epilepsy. The goal of the present analysis was to determine if the dose-response of brivaracetam as monotherapy would fall within the range associated with brivaracetam efficacy as adjunctive therapy. An existing brivaracetam population pharmacokinetic model consisting of first-order absorption, single compartment distribution, and first-order elimination components was extended by estimating the clearance changes due to co-administration of 12 widely prescribed AEDs. Data for the population pharmacokinetic analysis originated from three Phase III add-on trials and two terminated Phase III monotherapy trials. An existing population model of daily seizure rate versus brivaracetam daily average concentration was applied to the data from the three add-on trials. Simulations allowed the assessment of the combined impact of covariate effects on both the pharmacokinetics and the pharmacodynamics of brivaracetam, and indicated that in the absence of other AEDs, only marginal changes in the overall dose-response relationship would be expected. This suggests that brivaracetam can be used as monotherapy without dose modifications.
AuthorsRik Schoemaker, Janet R Wade, Joseph D'Souza, Armel Stockis
JournalEpilepsy research (Epilepsy Res) Vol. 137 Pg. 95-100 (11 2017) ISSN: 1872-6844 [Electronic] Netherlands
PMID28982069 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Anticonvulsants
  • Pyrrolidinones
  • brivaracetam
Topics
  • Adolescent
  • Adult
  • Aged
  • Anticonvulsants (pharmacokinetics, therapeutic use)
  • Computer Simulation
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Humans
  • Middle Aged
  • Models, Biological
  • Pyrrolidinones (pharmacokinetics, therapeutic use)
  • Seizures (blood, drug therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: